Nephro Care India Limited

NEPHROCAREHospital
108.25+0.00 (+0.00%)
As on 21 Jan 2026, 08:45 amMarket Closed

Fundamental Score

...

Nephro Care India Limited Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

8.38%
Poor

Return on Capital Employed

11.27%
Excellent

Operating Profit Margin (5Y)

16.80%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

65.09x

Market Capitalization

220.67 (Cr)

Industry P/E

52.84x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-11.42%
Excellent

YoY Quarterly Sales Growth

122.33%
Excellent

Sales Growth (5Y)

143.29%
Excellent

EPS Growth (5Y)

16.80%
Excellent

Profit Growth (5Y)

210.58%

Financial Health

Excellent

Debt to Equity

0.00x
Excellent

Interest Coverage

26.61x
Poor

Free Cash Flow (5Y)

-22.86 (Cr)

Ownership Structure

Good

Promoter Holding

61.47%
Poor

FII Holding

3.47%
Poor

DII Holding

1.04%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
61.47%
Promoter Holding
220.67 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of NEPHROCARE across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Operating Margins (16.80%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Strong Revenue Growth (122.33%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (143.29% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Excellent EPS Growth (16.80% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (210.58% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (26.61x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (61.47%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

9 factors identified

Below-Average Return on Equity (8.38%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Premium Valuation Risk (P/E: 65.09x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Profit Decline Concern (-11.42%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Negative Free Cash Flow (₹-22.86 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

Limited Institutional Interest (FII+DII: 4.51%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Financial Statements

Comprehensive financial data for Nephro Care India Limited

About NEPHROCARE

Company Details

Symbol:NEPHROCARE
Industry:Hospital
Sector:Hospital
Website:N/A

NEPHROCARE Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)8.38%
Return on Capital Employed11.27%
Operating Profit Margin (5Y)16.80%
Debt to Equity Ratio0.00
Interest Coverage Ratio26.61

Growth & Valuation

Sales Growth (5Y)143.29%
Profit Growth (5Y)210.58%
EPS Growth (5Y)16.80%
YoY Quarterly Profit Growth-11.42%
YoY Quarterly Sales Growth122.33%

Frequently Asked Questions

What is the current price of Nephro Care India Limited (NEPHROCARE)?

As of 21 Jan 2026, 08:45 am IST, Nephro Care India Limited (NEPHROCARE) is currently trading at ₹108.25. The stock has a market capitalization of ₹220.67 (Cr).

Is NEPHROCARE share price Overvalued or Undervalued?

NEPHROCARE is currently trading at a P/E ratio of 65.09x, compared to the industry average of 52.84x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Nephro Care India Limited share price?

Key factors influencing NEPHROCARE's price include its quarterly earnings growth (Sales Growth: 122.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Nephro Care India Limited a good stock for long-term investment?

Nephro Care India Limited shows a 5-year Profit Growth of 210.58% and an ROE of 8.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.

How does Nephro Care India Limited compare with its industry peers?

Nephro Care India Limited competes with major peers in the Hospital. Investors should compare NEPHROCARE's P/E of 65.09x and ROE of 8.38% against the industry averages to determine its competitive standing.

What is the P/E ratio of NEPHROCARE and what does it mean?

NEPHROCARE has a P/E ratio of 65.09x compared to the industry average of 52.84x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹65 for every ₹1 of annual earnings.

How is NEPHROCARE performing according to Bull Run's analysis?

NEPHROCARE has a Bull Run fundamental score of 57.1/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does NEPHROCARE belong to?

NEPHROCARE operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Nephro Care India Limited.

What is Return on Equity (ROE) and why is it important for NEPHROCARE?

NEPHROCARE has an ROE of 8.38%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Nephro Care India Limited generates profits from shareholders' equity.

How is NEPHROCARE's debt-to-equity ratio and what does it indicate?

NEPHROCARE has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is NEPHROCARE's dividend yield and is it a good dividend stock?

NEPHROCARE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has NEPHROCARE grown over the past 5 years?

NEPHROCARE has achieved 5-year growth rates of: Sales Growth 143.29%, Profit Growth 210.58%, and EPS Growth 16.80%.

What is the promoter holding in NEPHROCARE and why does it matter?

Promoters hold 61.47% of NEPHROCARE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is NEPHROCARE's market capitalization category?

NEPHROCARE has a market capitalization of ₹221 crores, placing it in the Small-cap category.

How volatile is NEPHROCARE stock?

NEPHROCARE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for NEPHROCARE?

NEPHROCARE has a 52-week high of ₹N/A and low of ₹N/A.

What is NEPHROCARE's operating profit margin trend?

NEPHROCARE has a 5-year average Operating Profit Margin (OPM) of 16.80%, indicating the company's operational efficiency.

How is NEPHROCARE's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 122.33% and YoY Profit Growth of -11.42%.

What is the institutional holding pattern in NEPHROCARE?

NEPHROCARE has FII holding of 3.47% and DII holding of 1.04%. Significant institutional holding often suggests professional confidence in the stock.